ArticleCureus2025
Incidence and Predictors of Pulmonary Embolism Recurrence and Mortality in Patients With Lung Cancers.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Pulmonary embolism (PE) is a serious and potentially fatal complication in lung cancer patients. This study aims to identify predictors of recurrent PE and related mortality in this population. Methods A retrospective review was conducted using electronic medical records from King Abdulaziz Medical Cities in Riyadh and Jeddah, Saudi Arabia. Lung cancer patients with confirmed initial PE were included. Data on demographics, clinical features, and laboratory values-including Eastern Cooperative Oncology Group (ECOG) performance status, systemic infections, serum albumin, and D-dimer levels-were collected. PE and its recurrence were confirmed by standard imaging techniques. The statistical analyses comprised descriptive statistics, analysis of the receiver operating characteristic (ROC) curve to establish the optimum cutoff values of the biomarkers, and logistic regression to identify predictors of PE recurrence and mortality. Results A total of 98 adult lung cancer patients with initial PE were identified. Of these, 19 (19.4%) experienced recurrent PE, with a mortality rate of 73.7% in this group. Recurrent PE was significantly associated with poor ECOG performance status and systemic infections. Laboratory findings showed that recurrent cases had lower serum albumin (≤ 20.5 mg/L) and higher D-dimer (≥ 6.5 mg/L) levels. Logistic regression revealed that adenocarcinoma type, systemic infection, elevated D-dimer, and low albumin were significant predictors of PE recurrence. Mortality was higher in the recurrence group compared to non-recurrence (73.7% vs. 44.3%, p = 0.021). Conclusion Recurrent PE occurs in 19.4% of lung cancer patients with initial PE and carries high mortality. Identified predictors warrant validation in larger studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.